Medication info
Jabia M Tablet 50/500 mg (Sitagliptin Hydrochloride Hydrate, Metformin Hydrochloride)

Jabia M Tablet 50/500 mg (Sitagliptin Hydrochloride Hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletSitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Unimed Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
60 tablets/box [10T/PTP*6]
Approval status
Active

MFDS item code 202302023 · Approved 2023.06.30 · Insurance code 649508350

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. Generally, take twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. Patients not currently receiving metformin: Take 1 tablet of this medicine 50/500 mg twice daily; the dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with inadequate glycemic control on metformin monotherapy: The recommended initial dose is the current metformin dose together with sitagliptin 50 mg twice daily (total daily dose 100 mg). Patients switching from combination therapy with sitagliptin and metformin: Treatment may be initiated at the current doses of sitagliptin and metformin. Patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial metformin dose should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. For patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that could increase the risk of lactic acidosis: The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. Discontinue this medicine immediately if renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2.

Ingredients

Manufacturer
Unimed Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by using sitagliptin and metformin together. When taken along with dietary management and exercise, it can effectively improve blood sugar levels. Therefore, it is used as a treatment for patients who have difficulty managing their blood sugar levels.

How to take

Adult dose

The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. Generally, take twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. Patients not currently receiving metformin: Take 1 tablet of this medicine 50/500 mg twice daily; the dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with inadequate glycemic control on metformin monotherapy: The recommended initial dose is the current metformin dose together with sitagliptin 50 mg twice daily (total daily dose 100 mg). Patients switching from combination therapy with sitagliptin and metformin: Treatment may be initiated at the current doses of sitagliptin and metformin. Patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial metformin dose should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. For patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that could increase the risk of lactic acidosis: The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. Discontinue this medicine immediately if renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2.

Precautions

This medication contains both sitagliptin and metformin, which help regulate blood sugar levels. First, sitagliptin may rarely cause allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, it should be discontinued immediately. Additionally, there is a risk of acute pancreatitis, which is inflammation of the pancreas, so if symptoms such as abdominal pain or vomiting occur, careful observation is necessary. Metformin can cause a rare side effect known as severe lactic acidosis, which occurs when lactic acid accumulates excessively in the body, leading to a dangerous condition; symptoms include muscle pain, weakness, and difficulty breathing. If these symptoms appear, consult a doctor immediately, and it should not be administered to patients with impaired kidney function. This medication should not be used in patients with moderately to severely impaired kidney function, those with acute heart disease, patients with severely compromised liver function, or women who are pregnant or breastfeeding. During use, it is important to avoid irregular meals or intense exercise, and caution should be exercised regarding blood sugar changes if taken with other medications. Also, hypoglycemia may occur; therefore, especially when taking it concurrently with insulin or sulfonylureas, blood sugar levels should be checked frequently and symptoms should be monitored. While taking this medication, regular kidney function and blood tests should be conducted, and since vitamin B12 levels may decrease, supplementation may be necessary. Consumption of alcohol should be avoided, especially in conditions of impaired liver function, as the risk of lactic acidosis increases. If surgery is planned, the medication should be temporarily stopped 48 hours before the surgery and resumed only after kidney function is confirmed to be normal post-surgery. If blisters appear on the skin or severe joint pain occurs, notify a doctor immediately and stop taking this medication. Lastly, this medication should not be used in individuals under 18 years or in pregnant or nursing women due to lack of established safety.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 19 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe joint pain with disability
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • dermatitis
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness and safety.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

60 tablets/box [10T/PTP*6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.